Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Targeting JNK3 for the treatment of neurodegenerative disorders.

Resnick L, Fennell M.

Drug Discov Today. 2004 Nov 1;9(21):932-9. Review.

PMID:
15501728
[PubMed - indexed for MEDLINE]
2.

JNK3 as a therapeutic target for neurodegenerative diseases.

Antoniou X, Falconi M, Di Marino D, Borsello T.

J Alzheimers Dis. 2011;24(4):633-42. doi: 10.3233/JAD-2011-091567. Review.

PMID:
21321401
[PubMed - indexed for MEDLINE]
3.

Targeting the JNK pathway for therapeutic benefit in CNS disease.

Bozyczko-Coyne D, Saporito MS, Hudkins RL.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):31-49. Review.

PMID:
12769633
[PubMed - indexed for MEDLINE]
4.

K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways.

Pan J, Wang G, Yang HQ, Hong Z, Xiao Q, Ren RJ, Zhou HY, Bai L, Chen SD.

Mol Pharmacol. 2007 Dec;72(6):1607-18. Epub 2007 Sep 13.

PMID:
17855652
[PubMed - indexed for MEDLINE]
Free Article
5.

Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease.

Pan J, Xiao Q, Sheng CY, Hong Z, Yang HQ, Wang G, Ding JQ, Chen SD.

Neurochem Int. 2009 Jun;54(7):418-25. doi: 10.1016/j.neuint.2009.01.013. Epub 2009 Jan 29.

PMID:
19428783
[PubMed - indexed for MEDLINE]
6.

Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases.

Saporito MS, Hudkins RL, Maroney AC.

Prog Med Chem. 2002;40:23-62. Review.

PMID:
12516522
[PubMed - indexed for MEDLINE]
7.

Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.

Fricker M, Lograsso P, Ellis S, Wilkie N, Hunt P, Pollack SJ.

Arch Biochem Biophys. 2005 Jun 15;438(2):195-205.

PMID:
15907786
[PubMed - indexed for MEDLINE]
8.

Deletion of the c-Jun N-terminal kinase 3 gene protects neonatal mice against cerebral hypoxic-ischaemic injury.

Pirianov G, Brywe KG, Mallard C, Edwards AD, Flavell RA, Hagberg H, Mehmet H.

J Cereb Blood Flow Metab. 2007 May;27(5):1022-32. Epub 2006 Oct 25.

PMID:
17063149
[PubMed - indexed for MEDLINE]
9.
10.

Different protection of K252a and N-acetyl-L-cysteine against amyloid-beta peptide-induced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades.

Xu Y, Hou XY, Liu Y, Zong YY.

J Neurosci Res. 2009 Mar;87(4):918-27. doi: 10.1002/jnr.21909.

PMID:
18951497
[PubMed - indexed for MEDLINE]
11.

JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities.

Mehan S, Meena H, Sharma D, Sankhla R.

J Mol Neurosci. 2011 Mar;43(3):376-90. doi: 10.1007/s12031-010-9454-6. Epub 2010 Sep 28. Review.

PMID:
20878262
[PubMed - indexed for MEDLINE]
12.

JNK signalling: a possible target to prevent neurodegeneration.

Borsello T, Forloni G.

Curr Pharm Des. 2007;13(18):1875-86. Review.

PMID:
17584114
[PubMed - indexed for MEDLINE]
13.

JNK inhibition as a potential strategy in treating Parkinson's disease.

Wang W, Ma C, Mao Z, Li M.

Drug News Perspect. 2004 Dec;17(10):646-54. Review.

PMID:
15696229
[PubMed - indexed for MEDLINE]
14.

The interleukin-1 system: an attractive and viable therapeutic target in neurodegenerative disease.

Allan SM, Pinteaux E.

Curr Drug Targets CNS Neurol Disord. 2003 Oct;2(5):293-302. Review.

PMID:
14529361
[PubMed - indexed for MEDLINE]
15.

c-Jun N-terminal kinase 3 deficiency protects neurons from axotomy-induced death in vivo through mechanisms independent of c-Jun phosphorylation.

Keramaris E, Vanderluit JL, Bahadori M, Mousavi K, Davis RJ, Flavell R, Slack RS, Park DS.

J Biol Chem. 2005 Jan 14;280(2):1132-41. Epub 2004 Nov 4.

PMID:
15528206
[PubMed - indexed for MEDLINE]
Free Article
16.

Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.

Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA Jr, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):315-9. doi: 10.1016/j.bmcl.2010.11.010. Epub 2010 Nov 5.

PMID:
21112785
[PubMed - indexed for MEDLINE]
17.

Development and optimization of a non-radioactive JNK3 assay.

Peifer C, Luik S, Thuma S, Herweh Y, Laufer S.

Comb Chem High Throughput Screen. 2006 Sep;9(8):613-8.

PMID:
17017881
[PubMed - indexed for MEDLINE]
18.

Truncation of the CNS-expressed JNK3 in a patient with a severe developmental epileptic encephalopathy.

Shoichet SA, Duprez L, Hagens O, Waetzig V, Menzel C, Herdegen T, Schweiger S, Dan B, Vamos E, Ropers HH, Kalscheuer VM.

Hum Genet. 2006 Jan;118(5):559-67. Epub 2005 Oct 25.

PMID:
16249883
[PubMed - indexed for MEDLINE]
19.

3D-QSAR studies of 1,2-diaryl-1H-benzimidazole derivatives as JNK3 inhibitors with protective effects in neuronal cells.

Kim MH, Ryu JS, Hah JM.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1639-42. doi: 10.1016/j.bmcl.2013.01.082. Epub 2013 Jan 29.

PMID:
23416008
[PubMed - indexed for MEDLINE]
20.

Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy.

Kuan CY, Burke RE.

Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):63-7. Review.

PMID:
15723614
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk